Etanercept in severe active rheumatoid arthritis: first Australian experience
Background: Etanercept reduces disease activity in adults with chronic rheumatoid arthritis (RA) who are resistant to other therapies. Medicare Australia Pharmaceutical Benefit Scheme subsidized treatment (since August 2003) restricts etanercept availability to a most drug-resistant RA population. The aim of the study was to assess the efficacy of etanercept in this unique group after 12 months of therapy. Methods: A prospective study of the first 50 consecutive private practice, adult RA...[Show more]
|Collections||ANU Research Publications|
|Source:||Internal Medicine Journal|
|01_Perera_Etanercept_in_severe_active_2006.pdf||123.34 kB||Adobe PDF||Request a copy|
Items in Open Research are protected by copyright, with all rights reserved, unless otherwise indicated.